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A B S T R A C T
Background: Gallbladder cancer (GC) is a relatively rare disease. To date, there are no studies describing the
epidemiology of this disease in Qatar.
Objective: To study the epidemiology of Gallbladder Cancer in Qatar.
Methods: A retrospective analysis of the cases of GC in Hamad General Hospital in Qatar from 2009 to 2016.
Results: Thirty-five patients presented with GC during the study period, 10 females (28.6%) and 25 males
(71.4%). Fourteen patients (40%) were diagnosed incidentally after laparoscopic cholecystectomy, 16 (48.6%)
were diagnosed pathologically, and 4 (11.4%) were diagnosed radiologically. The median age at diagnosis was
54 years (31–78). 74.3% of the disease occurred in patients less than 60 years old. Metastatic disease was
discovered in 25 patients (71.4%) versus no metastasis in 10 patients (28.6%). The most common sites for
metastasis were the liver (42.9%), peritoneum (25.7%), and lymph nodes (25.7%). Curative central hepatic
resection was done in 8 patients (22.9%). Pathology showed adenocarcinoma in 27 patients (77.1%), neu-
roendocrine tumor in 3 patients (8.6%) and high-grade dysplasia in 1 patient (2.9%). No histopathology was
available for 4 patients (11.4%). Twenty-eight patients (80.0%) had regular follow up, with 22 (62.9%) still
alive. Six patients (17.1%) died during follow up with survival after diagnosis ranging from 42 days to 6.8 years.
Conclusions: In Qatar, due to the unique demographics, GC is more common in males and younger age groups.
Most of the patients present late with metastasis, but curative resection is associated with long-term survival.
1. Introduction
Gallbladder cancer (GC) is a relatively rare disease with variable
incidence worldwide [1]. Most patients are usually diagnosed after la-
paroscopic cholecystectomy, and many patients usually present at a late
stage with poor prognosis [2]. To date, there is no data on the actual
incidence and epidemiology of this disease in the State of Qatar, despite
that the disease characteristics may differ in Qatar due to the unique
demographic profile of the population.
Qatar is a rapidly developing country with huge development pro-
jects that led to high influxes of migrant workers and professionals from
around the world [3]. The result is a multi-ethnic young adult popu-
lation, with continuous and high demographic turnover, as many mi-
grants reside for short periods before returning to their home countries.
Currently, Qatar's total population is about 2.5 million, with 99% < 65
years and 1% above 65 years old. Most of these migrants are not ac-
companied by their families, resulting in 79% of Qatar's population
being males and only 21% females [3]. Collectively, these factors reflect
substantially on the epidemiology and clinicopathologic characteristics
of Qatar's prevalent diseases.
The literature reveals several gaps. Given Qatar's distinctive de-
mographic profile and population characteristics, to date, there are no
studies of GC epidemiology and clinicopathologic features in Qatar, or
among populations of similar demographic features in the region. Such
paucity of data is a concern, considering the unique features of GC as a
biliary tract malignancy with wide regional variations, rare in most
western countries but much prevalent in other world regions, char-
acterized by lack of symptoms at the early stages, and hence difficulties
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in treatment [4]. In addition, patients' outcomes are overall bad, sur-
gery is the only potentially curative treatment [5], metastasis is
common [6], and the lack of a serosal layer of gallbladder adjacent to
the liver enables hepatic invasion/metastasis and is a major reason of
its dismal prognosis [7]. These factors highlight the need for up-to-date
information on the epidemiology, clinicopathological features, diag-
nosis and management of GC; and wide regional differences across
these features mandate examining the specific characteristics of GC
among our population.
Therefore, the current study assessed GC epidemiology and other
features in Qatar. Our institution is the National Referral Center for all
cancer patients in Qatar, receiving all GC cases diagnosed across the
country. Even cases diagnosed incidentally after surgery in secondary
care centers and private hospitals are eventually referred to this
National Referral Center. The specific objectives of the study were to:
• Describe GC epidemiology;
• Assess potential risk factors of GC (e.g. gallstones, gallbladder
polyps, BMI, environmental exposures, diabetes);
• Describe the mode of diagnosis, stage of disease at diagnosis and
pattern of metastases;
• Illustrate GC histopathological types;
• Demonstrate the management modalities undertaken; and,
• Analyze the survival of GC patients and the factors associated with
such survival.
Availability of accurate, up to date information on the epide-
miology, prevalence, histopathology, metastasis, and management
helps to assess the disease burden and guides the diagnostic and
treatment decisions, while contributing to the evidence base inter-
nationally. Such information will be relevant not only to Qatar, but also
to the neighboring nations in the region (e.g. United Arab Emirates,
Kuwait, and Bahrain) that have similar population characteristics.
2. Materials and methods
2.1. Ethics and setting
This retrospective study was conducted at Hamad General Hospital,
Doha (600-bed specialized facility). The Medical Research Centre at
Hamad Medical Corporation (equivalent to the Ministry of Health)
approved the study (IRB approved, Protocol #17090).
2.2. Registration
This study is registered with the Research Registry [8] (Research
Registry UIN: research registry 4551).
2.3. Procedures
In this retrospective study, we systematically searched the
Hepatobiliary multi-disciplinary team database at our institution and
identified all GC patients over a seven-year period (July 2009–August
2016).
2.4. Inclusion and exclusion criteria
All adult patients (≥18 years) newly diagnosed with GC were in-
cluded in the study, and the information extracted from their medical
records included: demographics, risk factor/s (BMI, diabetes, gall-
stones, gallbladder polyps, environmental exposure), date and method
of diagnosis, staging workup results, histopathological findings, treat-
ment modality and survival time until the most recent follow-up.
Patients< 18 years were excluded from the study.
2.5. Diagnosis and staging
GC diagnosis was classified as pre-, intra- or postoperative. When
patients were suspected to have GC preoperatively, the workup in-
cluded abdominal ultrasound (US), Computed tomography (CT) scan,
magnetic resonance imaging (MRI), with Positron emission tomography
(PET/CT) for staging, and the diagnosis was confirmed by CT or US-
guided core needle biopsy/fine needle aspiration cytology when fea-
sible. When GC was suspected intraoperatively, it was confirmed by
frozen section histopathology, which was the standard procedure at our
hospital. Incidental postoperative diagnosis was established by formal
histopathology after laparoscopic cholecystectomy. All patients were
staged following the American Joint Committee on Cancer TNM staging
manual (7th edition) [9].
2.6. Subgroup analyses
Overall and one-year survival were analyzed in relation to gender,
age, the method of diagnosis, surgical intervention and presence of
metastases.
2.7. Statistical analysis
The statistical software SPSS V. 22 (SPSS Inc., Chicago, US) was
used for the analysis, with significance level set at P < 0.05. For
continuous variables, the data was summarized as mean (± standard
deviation) and median with range; for categorical variables, we used
frequency (%). Kaplan- Meier curves were used for the calculation of
patient survival.
2.8. Reporting
This study is reported in line with the STROCSS guidelines [10].
3. Results
3.1. Descriptive epidemiology
Table 1 shows that 35 patients (10 females, 28.6%; 25 males,
71.4%) were diagnosed with GC during the study period. The mean age
at diagnosis was 52.5 (± 13.5 years), and the median age was 54 years
(range=31–78 years). About 75% of the cases occurred among pa-
tients< 60 years old. Patients’ ethnicities were East Asian (23 patients,
65.7%), Middle Eastern (8 patients, 22.9%), Qatari (3 patients, 8.6%),
and African (one patient, 2.9%).
3.2. Risk factors
Only 4 patients (11.4%) had diabetes. Mean BMI was 27.1 (± 10.5)
Kg/m2. None of the patients had a history of previous environmental
exposures or contact with occupational hazardous materials. On ultra-
sound imaging, 19 patients (54.3%) had gallstones ranging from tiny to
3.8 cm, and two patients (5.7%) had polyps (one with multiple tiny
polyps, the other with a 13mm polyp).
3.3. Diagnosis
Fourteen patients (40%) were diagnosed incidentally, and another
14 (40%) were diagnosed by pathology before surgery (12 patients by
core needle biopsy, 2 by fine needle aspiration cytology - FNAC). Three
patients (8.6%) were suspected to have cancer intraoperatively, and the
diagnosis was confirmed by intraoperative frozen section. Four patients
(11.4%) presented with advanced metastatic disease on imaging, and
no histopathology was undertaken.
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3.4. Metastases
Twenty-five patients (71.4%) had metastases at the time of diag-
nosis, while 10 patients (28.6%) were metastasis-free. Most common
sites of metastases were: liver (42.9%), peritoneum (25.7%) and re-
gional lymph nodes (25.7%); this was followed by lungs, supra-dia-
phragmatic lymph nodes, spleen, bone, and retroperitoneal lymph
nodes, each involved in 5.7% of the cases. One patient (2.9%) had
colonic hepatic flexure metastasis, and another (2.9%) had laparoscopic
port site involvement after cholecystectomy.
3.5. Pathology
Pathology was available for 31 patients and included: adenocarci-
noma (27 patients, 77.1%), neuroendocrine tumor (3 patients, 8.6% -
out of which one had pure large cell neuroendocrine tumor) and high-
grade dysplasia (1 patient, 2.9%). Four patients (11.4%) had no pa-
thology.
3.6. Surgical management
None of the patients diagnosed preoperatively with needle biopsy
had resection due to advanced disease. Eight patients (22.9%) had
curative central liver resection and lymphadenectomy. Of these, two
(5.7%) proceeded to resection following intraoperative diagnosis with
frozen section, while six patients (17.1%) were diagnosed incidentally
after laparoscopic cholecystectomy and were re-operated. One patient
had exploration laparotomy and was found to have peritoneal carci-
nomatosis, and only peritoneal biopsy with frozen section was done,
confirming the diagnosis.
3.7. Survival
Complete follow data was available for 28 patients, while 7 were
lost to follow up. Mean follow up was 8.6 ± 14.5 months, ranging from
0 days (one patient incidentally diagnosed after laparoscopic chole-
cystectomy but never returned for follow up after surgery) to 7 years
(one patient who died from myocardial infarction). Of the 28 patients
with complete follow up data, 22 were alive, and 6 were dead at the
time of writing of this manuscript.
Overall and one-year survival were analyzed in relation to gender,
age (above/below 50 years), the method of diagnosis, surgical inter-
vention and presence of metastases (Fig. 1). Overall survival was not
significantly associated with any of these factors, although patients
diagnosed incidentally and those who had surgical intervention tended
to have better survival (94.4% vs. 70.6%, P=0.58). In terms of one-
year survival, those who had any surgical intervention exhibited sig-
nificantly better survival than those without surgical intervention
(100% vs. 76.5%, P=0.02). Likewise, patients diagnosed incidentally
after laparoscopic cholecystectomy had significantly better survival
than those presenting with symptoms (100% vs. 77.8%, P=0.02).
4. Discussion
GC is relatively rare, with marked variations in incidence rates,
gender, ethnical and geographical distributions [1,11,12]. We diag-
nosed 35 GC cases in Qatar during the 7 years study period, i.e. an
average of 5 cases per year, or annual incidence of 0.2/100,000, which
represents the true incidence in Qatar, as our institution receives all
cancer cases in the country. This is less than the worldwide incidence of
1–2.5 per 100,000, and much less than the incidence in high-risk po-
pulations like the Mapuche Indians, where it can be up to 27.3/100000
[13,14].
In terms of gender, we observed a ≈1:3 GC female/male incidence
ratio, in contrast with the literature. Generally GC is more common in
females, with the female/male ratio ranging between>5:1 to 1:1
(average 2–3:1) [1]. Our reversed ratio (about 1:3) mirrors the popu-
lation profile in Qatar (21% females, 79% males) [3]. Although our
number of GC cases among Qataris was small (3 patients), yet it com-
prised 2 females and 1 male, agreeing with the gender ratio seen
worldwide, and also in line with that of other Middle Eastern countries
(Jordan) where the ratios ranged between 3:2 and 3.7:1, and with Saudi
Arabia where females comprsied 62% of the GC patients [15–17]. .
In terms of ethnicity, GC exhibits noticeable ethnic and geo-
graphical disparities across the world, [11,12,18]. Only one (2.9%) of
our patients was African, in support of the low GC incidence in African
countries, sometimes amounting to one third or one half lower than
those of industrialized countries [19]. Conversely, 23 (65.7%) of our
patients (20 males, 3 females) were East Asian, in agreement with re-
search in the USA that found remarkably elevated GC incidence rates
among Korean and Chinese migrants [20]. Likewise, 8 of our patients
(22.9%) were from Middle Eastern countries (non-Qatari nationals), in
support of others, where there was significantly higher age- and gender-
standardized proportional ratios for gallbladder and other biliary can-
cers (1.87) among Arabic immigrant population compared with non-
immigrants in the USA [21]. Others have highlighted the importance of
birthplace, length of stay, and effect of migration from high- to low-risk
regions in GC development and etiology, suggesting varied roles of
geographic, environmental, genetic and lifestyle factors [1,22–24].
In terms of age (Table 1), a notable contrast between our findings
Table 1
Patient characteristics (N=35).
Demography Value
Sex n (%)
Male 25 (71.4)
Female 10 (28.6)
Age (years)
Median 54
Range 31–78
Mean ± SD 52.5 ± 13.5
Age groups (years)
30-39 7 (20.0%)
40-49 8 (22.9%)
50-59 11 (31.4%)
60-69 4 (11.4%)
70-79 5 (14.3%)
Ethnicity n (%)
Qatari 3 (8.6)
Middle Eastern 8 (22.8)
East Asian 23 (65.7)
African 1 (2.9)
BMI (Mean± SD) 27.1 ± 10.5
Pathology n (%)
Adenocarcinoma 27 (77.1%)
Neuroendocrine tumors 3 (8.6%)
High grade dysplasia 1 (2.9%)
No histopathology 4 (1.4%)
Clinical n (%)
Mode of Presentation
Incidental at laparoscopy 14 (40)
Locally advanced 7 (20)
Metastatic 14 (40)
TNM
I 1 (2.9)
II 2 (5.7%)
III 3 (8.6)
IV 25 (71.4%)
Unknown 4 (11.4)
Diagnostic mode
Incidental 14 (40)
Frozen section 3 (8.6)
Core/Fine needle 14 (40)
Imaging only 4 (11.4)
Gall bladder stones (Yes) 19 (54.3)
Gall bladder polyp/s (Yes) 2 (5.7)
Metastasis at time of diagnosis (Yes) 25 (71.4%)
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and published studies [7], is the relatively younger age at diagnosis in
the current study (75% were<60 years old). Although the commonest
presentation of GC worldwide is between the 7th-8th decades [7], our
patients presented most commonly two decades younger, and 20% were
even < 40 years old at presentation. Our patients were also younger
than those reported from other neighboring countries e.g. Saudi Arabia,
where most patients were 66–70 years old [17]. The reasons behind our
younger age patients are difficult to speculate, but demographic and
ethnic factors might play a role. The key implication is that, in this
region, health professionals need to have a higher index of suspicion for
GC among younger patients, which calls for more proactive work-up
among this age group to rule out GC. Another point is that younger GC
patients have better survival, partly explained by the better perfor-
mance status and better chemotherapy tolerance [25] and this again
calls for more aggressive therapeutic interventions among these
younger patients.
As for risk factors, in terms of cholelithiasis, 19 of our patients
(54.3%) had gallstones that ranged from tiny to 3.8 cm. GC is usually
associated with gallstones [11], and while some studies [26,27] re-
ported a robust association between large gallstones (> 3 cm) and GC
risk; others [28] found no variation in GC risk by gallstone size.
As for gallbladder polyps, two patients (5.6%) had cholesterol
polyps. Gallbladder polyps on imaging workup are concerning, as any
polyp could represent GC cancer. Despite this, 95% of polyps are not
neoplastic, and only 5% are neoplastic (≈4% adenomas,< 1% malig-
nant). The progression from adenoma to carcinoma has not been es-
tablished in GC cancer as it has been in other cancers (e.g. colon cancer)
[1,7]. In support, none of the lesions in this cohort had associated
Fig. 1. Gall bladder cancer patient survival of (n= 35): Kaplan Mayer Curves. A: Overall survival; B: Survival by metastases at time of diagnosis; C: Survival by
gender; D: Survival by surgical resection.
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adenomatous changes.
The mean BMI was 27.1 (± 10.5) Kg/m2. Most studies found a
strong association between obesity and GC, more established in women
[29,30], while some found no association [31,32]. It is unclear whether
this association could be mediated by an increased tendency among
obese persons to develop gallstones [33]. Future studies could examine
such relationships.
Multiple environmental exposures (Radon, heavy metals, drugs e.g.
methyldopa and isoniazid), chronic bacterial infections (Salmonella,
Helicobacter), parasites (Clonorchis Sinensis), and diabetes could also
increase GC risk via various mechanisms, but none of our patients had
such exposure/s or infections, and we did not observe an association
between diabetes and GC in our sample [1,7,34,35].
In respect to the mode of diagnosis, 14 patients (40%) were diag-
nosed incidentally after laparoscopic cholecystectomy, supporting that
GC is commonly (47%) diagnosed incidentally [2]. A total of 71.4% of
our patients presented as stage IV, consistent with the literature, where
most GC patients presented with metastases, e.g. 75% in Saudi Arabia
[17], 47% in USA [2], and 78% in India [36].
Pathology was available for 31 patients (4 patients did not under-
take gallbladder resection or core needle biopsies), where 27 (87.0%)
were adenocarcinomas, 3 (9.7%) were neuroendocrine tumors (NET),
and one (3.2%) had high-grade dysplasia with no invasive component.
Our neuroendocrine tumors were of a higher percentage (9.7%) than
others, as these tumors are rare in other studies (1.3–2% of all GC
and<0.2% of all NETs [17,37,38]. One of our neuroendocrine tumors
was of the pure large cell variety, which is extremely rare, with our case
being the 8th case described in the literature. Nevertheless, we agree
with the literature in that most adenocarcinoma cases were poorly
(50%) or moderately differentiated (38.5%) [7,18,39].
In terms of survival, GC has a poor prognosis despite advances in
diagnostic/therapeutic modalities [2,15,40]. Others noted that median
survival (72 months) was significantly better for patients incidentally
diagnosed after cholecystectomy who exhibited no evidence of disease
on re-exploration, compared to those with residual disease [2,41]. We
observed no associations between the age at diagnosis, patient's gender,
or surgical resection on survival, but it is possible that our small sample
size and heterogeneity of the patients' GC stages meant that the study
might not have had sufficient power to address such questions. In our
cohort, patients who underwent liver resection with intent-to-cure
tended to have better survival; however, the difference was not statis-
tically significant (Fig. 1). Among a cohort of 102 patients [6], complete
surgical resection was the main variable associated with long-term
survival (63.2% five-year survival vs. 0% in un-resected patients), and
patients who presented incidentally had a higher chance of resectability
and better survival than patients who presented symptomatically [6].
Our patients exhibited similar results, but these were not statistically
significant.
This study has limitations. Data about the chemical composition of
the stones would have contributed information about any associations
between composition and GC. A larger sample size would have per-
mitted comparisons between the different patient subgroups.
Nonetheless, our sample (35 GC patients across a 7 years) is comparable
to studies from Iran (37 cases over three decades) [42] and Jordan (66
cases over 19 years) [15]. Likewise, despite that the population of Saudi
Arabia is about 11 times larger than Qatar, a study reported 76 patients
over 7 years [17]. The current study has strengths: it is representative of
the whole state of Qatar, and it bridges the lack of GC studies in the
Arabian countries of the Gulf region that have similar population
structures. More importantly, it generated new findings, notably the
younger age at diagnosis, which is unique to this region, hence adding
new insights to what is already known.
5. Conclusion
GC is a silent malignancy that expresses itself clinically at an
advanced stage, where curative efforts are likely to be futile, and there
are no current, reliable screening methods. This renders the identifi-
cation of high-risk groups extremely important because raising aware-
ness about their high risk is the way to encourage higher diagnostic
efforts upon the least suspicion of the disease. Such actions may lead to
earlier diagnosis and better survival. In Qatar, GC is more common in
males and among younger age groups due to the unique population
gender and age structures. Most patients present late with frequent
metastases at diagnosis. Curative resection, when possible, presents the
only hope for a better outcome.
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